Pathophysiological roles of Pim-3 kinase in pancreatic cancer development and progression

World Journal of Gastroenterology

Volumn 20, Issue 28, 2014, Pages 9392-9404

  Li, Ying Yi ^a,b,c   Mukaida, Naofumi ^c  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c KANAZAWA UNIVERSITY   (Japan)

Author keywords

Apoptosis; C Myc; Cell Cycle; Ets 1; Pancreatic cancer; Serine threonine kinase; Translationally controlled tumor protein; Vascular endothelium growth factor

Indexed keywords

MESSENGER RNA; PROTEIN KINASE PIM 1; PROTEIN KINASE PIM 2; PROTEIN KINASE PIM 3; PROTEIN KINASE PIM 3 INHIBITOR; PROTEIN SERINE THREONINE KINASE; PROTEIN SERINE THREONINE KINASE INHIBITOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ONCOPROTEIN; PIM3 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

APOPTOSIS; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CARCINOMA CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; CRYSTAL STRUCTURE; DISEASE ASSOCIATION; ENZYME ACTIVITY; HUMAN; IN VITRO STUDY; NONHUMAN; PANCREAS CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN STRUCTURE; TRANSCRIPTION REGULATION; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; AMINO ACID SEQUENCE; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL TRANSFORMATION; CHEMISTRY; DISEASE COURSE; DRUG EFFECTS; ENZYMOLOGY; GENETICS; METABOLISM; MOLECULAR GENETICS; MOLECULARLY TARGETED THERAPY; PANCREATIC NEOPLASMS; PATHOLOGY; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; HUMANS; MOLECULAR SEQUENCE DATA; MOLECULAR TARGETED THERAPY; PANCREATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84908884320     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i28.9392     Document Type: Article

References (108)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29 [PMID: 22237781 DOI: 10.3322/caac.20138]
2. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004; 363: 1049-1057 [PMID: 15051286 DOI: 10.1016/S0140-6736(04)15841-8]
3. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300 [PMID: 20610543 DOI: 10.3322/caac.20073]
4. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet 2011; 378: 607-620 [PMID: 21620466 DOI: 10.1016/S0140-6736(10)62307-0]
5. Li YY, Popivanova BK, Nagai Y, Ishikura H, Fujii C, Mukaida N. Pim-3, a proto-oncogene with serine/threonine kinase activity, is aberrantly expressed in human pancreatic cancer and phosphorylates bad to block bad-mediated apoptosis in human pancreatic cancer cell lines. Cancer Res 2006; 66: 6741-6747 [PMID: 16818649 DOI: 10.1158/0008-5472. CAN-05-4272]
6. Xu D, Cobb MG, Gavilano L, Witherspoon SM, Williams D, White CD, Taverna P, Bednarski BK, Kim HJ, Baldwin AS, Baines AT. Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine. Cancer Biol Ther 2013; 14: 492-501 [PMID: 23760491 DOI: 10.4161/cbt.24343]
7. Konietzko U, Kauselmann G, Scafidi J, Staubli U, Mikkers H, Berns A, Schweizer M, Waltereit R, Kuhl D. Pim kinase expression is induced by LTP stimulation and required for the consolidation of enduring LTP. EMBO J 1999; 18: 3359-3369 [PMID: 10369676 DOI: 10.1093/emboj/18.12.3359]
8. Mikkers H, Allen J, Knipscheer P, Romeijn L, Hart A, Vink E, Berns A. High-throughput retroviral tagging to identify components of specific signaling pathways in cancer. Nat Genet 2002; 32: 153-159 [PMID: 12185366 DOI: 10.1038/ng950]
9. Cuypers HT, Selten G, Quint W, Zijlstra M, Maandag ER, Boelens W, van Wezenbeek P, Melief C, Berns A. Murine leukemia virus-induced T-cell lymphomagenesis: integration of proviruses in a distinct chromosomal region. Cell 1984; 37: 141-150 [PMID: 6327049]
10. van Lohuizen M, Verbeek S, Krimpenfort P, Domen J, Saris C, Radaszkiewicz T, Berns A. Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukemia virus-induced tumors. Cell 1989; 56: 673-682 [PMID: 2537153]
11. Breuer ML, Cuypers HT, Berns A. Evidence for the involvement of pim-2, a new common proviral insertion site, in progression of lymphomas. EMBO J 1989; 8: 743-748 [PMID: 2721500]
12. Feldman JD, Vician L, Crispino M, Tocco G, Marcheselli VL, Bazan NG, Baudry M, Herschman HR. KID-1, a protein kinase induced by depolarization in brain. J Biol Chem 1998; 273: 16535-16543 [PMID: 9632723]
13. Fujii C, Nakamoto Y, Lu P, Tsuneyama K, Popivanova BK, Kaneko S, Mukaida N. Aberrant expression of serine/threonine kinase Pim-3 in hepatocellular carcinoma development and its role in the proliferation of human hepatoma cell lines. Int J Cancer 2005; 114: 209-218 [PMID: 15540201 DOI: 10.1002/ijc.20719]
14. Mukaida N, Wang YY, Li YY. Roles of Pim-3, a novel survival kinase, in tumorigenesis. Cancer Sci 2011; 102: 1437-1442 [PMID: 21518143 DOI: 10.1111/j.1349-7006.2011.01966.x]
15. Nawijn MC, Alendar A, Berns A. For better or for worse: the role of Pim oncogenes in tumorigenesis. Nat Rev Cancer 2011; 11: 23-34 [PMID: 21150935 DOI: 10.1038/nrc2986]
16. Brault L, Gasser C, Bracher F, Huber K, Knapp S, Schwaller J. PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers. Haematologica 2010; 95: 1004-1015 [PMID: 20145274 DOI: 10.3324/haematol.2009.017079]
17. Blanco-Aparicio C, Carnero A. Pim kinases in cancer: diagnostic, prognostic and treatment opportunities. Biochem Pharmacol 2013; 85: 629-643 [PMID: 23041228 DOI: 10.1016/j.bcp.2012.09.018]
18. Qian KC, Wang L, Hickey ER, Studts J, Barringer K, Peng C, Kronkaitis A, Li J, White A, Mische S, Farmer B. Structural basis of constitutive activity and a unique nucleotide binding mode of human Pim-1 kinase. J Biol Chem 2005; 280: 6130-6137 [PMID: 15525646 DOI: 10.1074/jbc.M409123200]
19. Bullock AN, Debreczeni J, Amos AL, Knapp S, Turk BE. Structure and substrate specificity of the Pim-1 kinase. J Biol Chem 2005; 280: 41675-41682 [PMID: 16227208 DOI: 10.1074/jbc.M510711200]
20. Bullock AN, Russo S, Amos A, Pagano N, Bregman H, Debreczeni JE, Lee WH, von Delft F, Meggers E, Knapp S. Crystal structure of the PIM2 kinase in complex with an organoruthenium inhibitor. PLoS One 2009; 4: e7112 [PMID: 19841674 DOI: 10.1371/journal.pone.0007112]
21. Kumar A, Mandiyan V, Suzuki Y, Zhang C, Rice J, Tsai J, Artis DR, Ibrahim P, Bremer R. Crystal structures of proto-oncogene kinase Pim1: a target of aberrant somatic hypermutations in diffuse large cell lymphoma. J Mol Biol 2005; 348: 183-193 [PMID: 15808862 DOI: 10.1016/j.jmb.2005.02.039]
22. Jacobs MD, Black J, Futer O, Swenson L, Hare B, Fleming M, Saxena K. Pim-1 ligand-bound structures reveal the mechanism of serine/threonine kinase inhibition by LY294002. J Biol Chem 2005; 280: 13728-13734 [PMID: 15657054 DOI: 10.1074/jbc.M413155200]
23. Zhang P, Wang H, Min X, Wang Y, Tang J, Cheng J, Li D, Chen X, Cheng F, Wang N, Yang H. Pim-3 is expressed in endothelial cells and promotes vascular tube formation. J Cell Physiol 2009; 220: 82-90 [PMID: 19229879 DOI: 10.1002/jcp.21733]
24. Lu A, Tang Y, Ran R, Clark JF, Aronow BJ, Sharp FR. Genomics of the periinfarction cortex after focal cerebral ischemia. J Cereb Blood Flow Metab 2003; 23: 786-810 [PMID: 12843783 DOI: 10.1097/01.WCB.0000062340.80057.06]
25. Liu D, He M, Yi B, Guo WH, Que AL, Zhang JX. Pim-3 protects against cardiomyocyte apoptosis in anoxia/reoxygenation injury via p38-mediated signal pathway. Int J Biochem Cell Biol 2009; 41: 2315-2322 [PMID: 19505587 DOI: 10.1016/j.biocel.2009.05.021]
26. Eichmann A, Yuan L, Bréant C, Alitalo K, Koskinen PJ. Developmental expression of pim kinases suggests functions also outside of the hematopoietic system. Oncogene 2000; 19: 1215-1224 [PMID: 10713710 DOI: 10.1038/sj.onc.1203355]
27. Deneen B, Welford SM, Ho T, Hernandez F, Kurland I, Denny CT. PIM3 proto-oncogene kinase is a common transcriptional target of divergent EWS/ETS oncoproteins. Mol Cell Biol 2003; 23: 3897-3908 [PMID: 12748291]
28. Yang XY, Ren CP, Wang L, Li H, Jiang CJ, Zhang HB, Zhao M, Yao KT. Identification of differentially expressed genes in metastatic and non-metastatic nasopharyngeal carcinoma cells by suppression subtractive hybridization. Cell Oncol 2005; 27: 215-223 [PMID: 16308470]
29. Popivanova BK, Li YY, Zheng H, Omura K, Fujii C, Tsuneyama K, Mukaida N. Proto-oncogene, Pim-3 with serine/threonine kinase activity, is aberrantly expressed in human colon cancer cells and can prevent Bad-mediated apoptosis. Cancer Sci 2007; 98: 321-328 [PMID: 17270021 DOI: 10.1111/j.1349-7006.2007.00390.x]
30. Zheng HC, Tsuneyama K, Takahashi H, Miwa S, Sugiyama T, Popivanova BK, Fujii C, Nomoto K, Mukaida N, Takano Y. Aberrant Pim-3 expression is involved in gastric adenomaadenocarcinoma sequence and cancer progression. J Cancer Res Clin Oncol 2008; 134: 481-488 [PMID: 17876606 DOI: 10.1007/s00432-007-0310-1]
31. Arvand A, Denny CT. Biology of EWS/ETS fusions in Ewing's family tumors. Oncogene 2001; 20: 5747-5754 [PMID: 11607824 DOI: 10.1038/sj.onc.1204598]
32. Li YY, Wu Y, Tsuneyama K, Baba T, Mukaida N. Essential contribution of Ets-1 to constitutive Pim-3 expression in human pancreatic cancer cells. Cancer Sci 2009; 100: 396-404 [PMID: 19154409 DOI: 10.1111/j.1349-7006.2008.01059.x]
33. Aksoy I, Sakabedoyan C, Bourillot PY, Malashicheva AB, Mancip J, Knoblauch K, Afanassieff M, Savatier P. Selfrenewal of murine embryonic stem cells is supported by the serine/threonine kinases Pim-1 and Pim-3. Stem Cells 2007; 25: 2996-3004 [PMID: 17717068 DOI: 10.1634/stemcells. 2007-0066]
34. Zhu N, Ramirez LM, Lee RL, Magnuson NS, Bishop GA, Gold MR. CD40 signaling in B cells regulates the expression of the Pim-1 kinase via the NF-kappa B pathway. J Immunol 2002; 168: 744-754 [PMID: 11777968]
35. Ito H, Duxbury M, Benoit E, Clancy TE, Zinner MJ, Ashley SW, Whang EE. Prostaglandin E2 enhances pancreatic cancer invasiveness through an Ets-1-dependent induction of matrix metalloproteinase-2. Cancer Res 2004; 64: 7439-7446 [PMID: 15492268 DOI: 10.1158/0008-5472.CAN-04-1177]
36. Safe S, Abdelrahim M. Sp transcription factor family and its role in cancer. Eur J Cancer 2005; 41: 2438-2448 [PMID: 16209919 DOI: 10.1016/j.ejca.2005.08.006]
37. Sharrocks AD. The ETS-domain transcription factor family. Nat Rev Mol Cell Biol 2001; 2: 827-837 [PMID: 11715049 DOI: 10.1038/35099076]
38. Hoover DS, Wingett DG, Zhang J, Reeves R, Magnuson NS. Pim-1 protein expression is regulated by its 5′-untranslated region and translation initiation factor elF-4E. Cell Growth Differ 1997; 8: 1371-1380 [PMID: 9419425]
39. Culjkovic B, Topisirovic I, Skrabanek L, Ruiz-Gutierrez M, Borden KL. eIF4E is a central node of an RNA regulon that governs cellular proliferation. J Cell Biol 2006; 175: 415-426 [PMID: 17074885 DOI: 10.1083/jcb.200607020]
40. Ma J, Arnold HK, Lilly MB, Sears RC, Kraft AS. Negative regulation of Pim-1 protein kinase levels by the B56beta subunit of PP2A. Oncogene 2007; 26: 5145-5153 [PMID: 17297438 DOI: 10.1038/sj.onc.1210323]
41. Losman JA, Chen XP, Vuong BQ, Fay S, Rothman PB. Protein phosphatase 2A regulates the stability of Pim protein kinases. J Biol Chem 2003; 278: 4800-4805 [PMID: 12473674 DOI: 10.1074/jbc.M208246200]
42. Thomas M, Lange-Grünweller K, Weirauch U, Gutsch D, Aigner A, Grünweller A, Hartmann RK. The proto-oncogene Pim-1 is a target of miR-33a. Oncogene 2012; 31: 918-928 [PMID: 21743487 DOI: 10.1038/onc.2011.278]
43. Kim KT, Carroll AP, Mashkani B, Cairns MJ, Small D, Scott RJ. MicroRNA-16 is down-regulated in mutated FLT3 expressing murine myeloid FDC-P1 cells and interacts with Pim-1. PLoS One 2012; 7: e44546 [PMID: 22970245 DOI: 10.1371/journal.pone.0044546]
44. Katare R, Caporali A, Zentilin L, Avolio E, Sala-Newby G, Oikawa A, Cesselli D, Beltrami AP, Giacca M, Emanueli C, Madeddu P. Intravenous gene therapy with PIM-1 via a cardiotropic viral vector halts the progression of diabetic cardiomyopathy through promotion of prosurvival signaling. Circ Res 2011; 108: 1238-1251 [PMID: 21474815 DOI: 10.1161/CIRCRESAHA.110.239111]
45. Eiring AM, Harb JG, Neviani P, Garton C, Oaks JJ, Spizzo R, Liu S, Schwind S, Santhanam R, Hickey CJ, Becker H, Chandler JC, Andino R, Cortes J, Hokland P, Huettner CS, Bhatia R, Roy DC, Liebhaber SA, Caligiuri MA, Marcucci G, Garzon R, Croce CM, Calin GA, Perrotti D. miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell 2010; 140: 652-665 [PMID: 20211135 DOI: 10.1016/j.cell.2010.01.007]
46. Huang X, Ding L, Bennewith KL, Tong RT, Welford SM, Ang KK, Story M, Le QT, Giaccia AJ. Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Mol Cell 2009; 35: 856-867 [PMID: 19782034 DOI: 10.1016/j.molcel.2009.09.006]
47. Zhang F, Liu B, Wang Z, Yu XJ, Ni QX, Yang WT, Mukaida N, Li YY. A novel regulatory mechanism of Pim-3 kinase stability and its involvement in pancreatic cancer progression. Mol Cancer Res 2013; 11: 1508-1520 [PMID: 24165482 DOI: 10.1158/1541-7786.MCR-13-0389]
48. Yang E, Zha J, Jockel J, Boise LH, Thompson CB, Korsmeyer SJ. Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 1995; 80: 285-291 [PMID: 7834748]
49. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L) Cell 1996; 87: 619-628 [PMID: 8929531]
50. Aho TL, Sandholm J, Peltola KJ, Mankonen HP, Lilly M, Koskinen PJ. Pim-1 kinase promotes inactivation of the proapoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site. FEBS Lett 2004; 571: 43-49 [PMID: 15280015 DOI: 10.1016/j.febslet.2004.06.050]
51. Yan B, Zemskova M, Holder S, Chin V, Kraft A, Koskinen PJ, Lilly M. The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death. J Biol Chem 2003; 278: 45358-45367 [PMID: 12954615 DOI: 10.1074/jbc. M307933200]
52. Liu LM, Zhang JX, Wang XP, Guo HX, Deng H, Luo J. Pim-3 protects against hepatic failure in D-galactosamine (D-GalN)-sensitized rats. Eur J Clin Invest 2010; 40: 127-138 [PMID: 20039932 DOI: 10.1111/j.1365-2362.2009.02235.x]
53. Breggia AC, Wojchowski DM, Himmelfarb J. JAK2/Y343/STAT5 signaling axis is required for erythropoietin-mediated protection against ischemic injury in primary renal tubular epithelial cells. Am J Physiol Renal Physiol 2008; 295: F1689-F1695 [PMID: 18815218 DOI: 10.1152/ajprenal. 90333.2008]
54. Chang M, Kanwar N, Feng E, Siu A, Liu X, Ma D, Jongstra J. PIM kinase inhibitors downregulate STAT3(Tyr705) phosphorylation. Mol Cancer Ther 2010; 9: 2478-2487 [PMID: 20667852 DOI: 10.1158/1535-7163.MCT-10-0321]
55. Zhang Y, Wang Z, Li X, Magnuson NS. Pim kinase-dependent inhibition of c-Myc degradation. Oncogene 2008; 27: 4809-4819 [PMID: 18438430 DOI: 10.1038/onc.2008.123]
56. Winn LM, Lei W, Ness SA. Pim-1 phosphorylates the DNA binding domain of c-Myb. Cell Cycle 2003; 2: 258-262 [PMID: 12734436]
57. Chen XP, Losman JA, Cowan S, Donahue E, Fay S, Vuong BQ, Nawijn MC, Capece D, Cohan VL, Rothman P. Pim serine/threonine kinases regulate the stability of Socs-1 protein. Proc Natl Acad Sci USA 2002; 99: 2175-2180 [PMID: 11854514 DOI: 10.1073/pnas.042035699]
58. Peltola KJ, Paukku K, Aho TL, Ruuska M, Silvennoinen O, Koskinen PJ. Pim-1 kinase inhibits STAT5-dependent transcription via its interactions with SOCS1 and SOCS3. Blood 2004; 103: 3744-3750 [PMID: 14764533 DOI: 10.1182/blood-2003-09-3126]
59. Gu JJ, Wang Z, Reeves R, Magnuson NS. PIM1 phosphorylates and negatively regulates ASK1-mediated apoptosis. Oncogene 2009; 28: 4261-4271 [PMID: 19749799 DOI: 10.1038/onc.2009.276]
60. Peng C, Knebel A, Morrice NA, Li X, Barringer K, Li J, Jakes S, Werneburg B, Wang L. Pim kinase substrate identification and specificity. J Biochem 2007; 141: 353-362 [PMID: 17234686 DOI: 10.1093/jb/mvm040]
61. Mochizuki T, Kitanaka C, Noguchi K, Muramatsu T, Asai A, Kuchino Y. Physical and functional interactions between Pim-1 kinase and Cdc25A phosphatase. Implications for the Pim-1-mediated activation of the c-Myc signaling pathway. J Biol Chem 1999; 274: 18659-18666 [PMID: 10373478]
62. Bachmann M, Hennemann H, Xing PX, Hoffmann I, Möröy T. The oncogenic serine/threonine kinase Pim-1 phosphorylates and inhibits the activity of Cdc25C-associated kinase 1 (C-TAK1): a novel role for Pim-1 at the G2/M cell cycle checkpoint. J Biol Chem 2004; 279: 48319-48328 [PMID: 15319445 DOI: 10.1074/jbc.M404440200]
63. Wang Z, Bhattacharya N, Mixter PF, Wei W, Sedivy J, Magnuson NS. Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by Pim-1 kinase. Biochim Biophys Acta 2002; 1593: 45-55 [PMID: 12431783]
64. Zhang Y, Wang Z, Magnuson NS. Pim-1 kinase-dependent phosphorylation of p21Cip1/WAF1 regulates its stability and cellular localization in H1299 cells. Mol Cancer Res 2007; 5: 909-922 [PMID: 17855660 DOI: 10.1158/1541-7786. MCR-06-0388]
65. Morishita D, Katayama R, Sekimizu K, Tsuruo T, Fujita N. Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels. Cancer Res 2008; 68: 5076-5085 [PMID: 18593906 DOI: 10.1158/0008-5472.CAN-08-0634]
66. Wang YY, Taniguchi T, Baba T, Li YY, Ishibashi H, Mukaida N. Identification of a phenanthrene derivative as a potent anticancer drug with Pim kinase inhibitory activity. Cancer Sci 2012; 103: 107-115 [PMID: 21981263 DOI: 10.1111/j.1349-7006.2011.02117.x]
67. Wu Y, Wang YY, Nakamoto Y, Li YY, Baba T, Kaneko S, Fujii C, Mukaida N. Accelerated hepatocellular carcinoma development in mice expressing the Pim-3 transgene selectively in the liver. Oncogene 2010; 29: 2228-2237 [PMID: 20101231 DOI: 10.1038/onc.2009.504]
68. Mikkers H, Nawijn M, Allen J, Brouwers C, Verhoeven E, Jonkers J, Berns A. Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors. Mol Cell Biol 2004; 24: 6104-6115 [PMID: 15199164 DOI: 10.1128/MCB.24.13.6104-6115.2004]
69. Beharry Z, Mahajan S, Zemskova M, Lin YW, Tholanikunnel BG, Xia Z, Smith CD, Kraft AS. The Pim protein kinases regulate energy metabolism and cell growth. Proc Natl Acad Sci USA 2011; 108: 528-533 [PMID: 21187426 DOI: 10.1073/pnas.1013214108]
70. Zippo A, De Robertis A, Serafini R, Oliviero S. PIM1-dependent phosphorylation of histone H3 at serine 10 is required for MYC-dependent transcriptional activation and oncogenic transformation. Nat Cell Biol 2007; 9: 932-944 [PMID: 17643117 DOI: 10.1038/ncb1618]
71. Vlacich G, Nawijn MC, Webb GC, Steiner DF. Pim3 negatively regulates glucose-stimulated insulin secretion. Islets 2010; 2: 308-317 [PMID: 21099329]
72. Amaravadi R, Thompson CB. The survival kinases Akt and Pim as potential pharmacological targets. J Clin Invest 2005; 115: 2618-2624 [PMID: 16200194 DOI: 10.1172/JCI26273]
73. Lindsley CW. The Akt/PKB family of protein kinases: a review of small molecule inhibitors and progress towards target validation: a 2009 update. Curr Top Med Chem 2010; 10: 458-477 [PMID: 20180757]
74. Cheng F, Weidner-Glunde M, Varjosalo M, Rainio EM, Lehtonen A, Schulz TF, Koskinen PJ, Taipale J, Ojala PM. KSHV reactivation from latency requires Pim-1 and Pim-3 kinases to inactivate the latency-associated nuclear antigen LANA. PLoS Pathog 2009; 5: e1000324 [PMID: 19266083 DOI: 10.1371/journal.ppat.1000324]
75. Major MB, Roberts BS, Berndt JD, Marine S, Anastas J, Chung N, Ferrer M, Yi X, Stoick-Cooper CL, von Haller PD, Kategaya L, Chien A, Angers S, MacCoss M, Cleary MA, Arthur WT, Moon RT. New regulators of Wnt/beta-catenin signaling revealed by integrative molecular screening. Sci Signal 2008; 1: ra12 [PMID: 19001663 DOI: 10.1126/scisignal. 2000037]
76. Verbeek S, van Lohuizen M, van der Valk M, Domen J, Kraal G, Berns A. Mice bearing the E mu-myc and E mupim- 1 transgenes develop pre-B-cell leukemia prenatally. Mol Cell Biol 1991; 11: 1176-1179 [PMID: 1990273]
77. Yang H, Wang Y, Qian H, Zhang P, Huang C. Pim protein kinase-3 is regulated by TNF-α and promotes endothelial cell sprouting. Mol Cells 2011; 32: 235-241 [PMID: 21870113 DOI: 10.1007/s10059-011-1026-z]
78. Red-Horse K, Crawford Y, Shojaei F, Ferrara N. Endothelium-microenvironment interactions in the developing embryo and in the adult. Dev Cell 2007; 12: 181-194 [PMID: 17276337 DOI: 10.1016/j.devcel.2007.01.013]
79. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005; 438: 967-974 [PMID: 16355214 DOI: 10.1038/nature04483]
80. Niedergethmann M, Hildenbrand R, Wostbrock B, Hartel M, Sturm JW, Richter A, Post S. High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas. Pancreas 2002; 25: 122-129 [PMID: 12142733]
81. Wang C, Li HY, Liu B, Huang S, Wu L, Li YY. Pim-3 promotes the growth of human pancreatic cancer in the orthotopic nude mouse model through vascular endothelium growth factor. J Surg Res 2013; 185: 595-604 [PMID: 23845873 DOI: 10.1016/j.jss.2013.06.004]
82. Nagy JA, Chang SH, Shih SC, Dvorak AM, Dvorak HF. Heterogeneity of the tumor vasculature. Semin Thromb Hemost 2010; 36: 321-331 [PMID: 20490982 DOI: 10.1055/s-0030-1253454]
83. Shah N, Pang B, Yeoh KG, Thorn S, Chen CS, Lilly MB, Salto-Tellez M. Potential roles for the PIM1 kinase in human cancer - a molecular and therapeutic appraisal. Eur J Cancer 2008; 44: 2144-2151 [PMID: 18715779 DOI: 10.1016/j.ejca.2008.06.044]
84. Bachmann M, Möröy T. The serine/threonine kinase Pim-1. Int J Biochem Cell Biol 2005; 37: 726-730 [PMID: 15694833 DOI: 10.1016/j.biocel.2004.11.005]
85. Weirauch U, Beckmann N, Thomas M, Grünweller A, Huber K, Bracher F, Hartmann RK, Aigner A. Functional role and therapeutic potential of the pim-1 kinase in colon carcinoma. Neoplasia 2013; 15: 783-794 [PMID: 23814490]
86. Guo S, Mao X, Chen J, Huang B, Jin C, Xu Z, Qiu S. Overexpression of Pim-1 in bladder cancer. J Exp Clin Cancer Res 2010; 29: 161 [PMID: 21143989 DOI: 10.1186/1756-9966-29-161]
87. Nga ME, Swe NN, Chen KT, Shen L, Lilly MB, Chan SP, Salto-Tellez M, Das K. PIM-1 kinase expression in adipocytic neoplasms: diagnostic and biological implications. Int J Exp Pathol 2010; 91: 34-43 [PMID: 19878356 DOI: 10.1111/j.1365-2613.2009.00673.x]
88. Hu XF, Li J, Vandervalk S, Wang Z, Magnuson NS, Xing PX. PIM-1-specific mAb suppresses human and mouse tumor growth by decreasing PIM-1 levels, reducing Akt phosphorylation, and activating apoptosis. J Clin Invest 2009; 119: 362-375 [PMID: 19147983 DOI: 10.1172/JCI33216]
89. Morishita D, Takami M, Yoshikawa S, Katayama R, Sato S, Kukimoto-Niino M, Umehara T, Shirouzu M, Sekimizu K, Yokoyama S, Fujita N. Cell-permeable carboxyl-terminal p27(Kip1) peptide exhibits anti-tumor activity by inhibiting Pim-1 kinase. J Biol Chem 2011; 286: 2681-2688 [PMID: 21062737 DOI: 10.1074/jbc.M109.092452]
90. Holder S, Zemskova M, Zhang C, Tabrizizad M, Bremer R, Neidigh JW, Lilly MB. Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase. Mol Cancer Ther 2007; 6: 163-172 [PMID: 17218638 DOI: 10.1158/1535-7163.MCT-06-0397]
91. Chen LS, Redkar S, Bearss D, Wierda WG, Gandhi V. Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. Blood 2009; 114: 4150-4157 [PMID: 19734450 DOI: 10.1182/blood-2009-03-212852]
92. Pogacic V, Bullock AN, Fedorov O, Filippakopoulos P, Gasser C, Biondi A, Meyer-Monard S, Knapp S, Schwaller J. Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity. Cancer Res 2007; 67: 6916-6924 [PMID: 17638903 DOI: 10.1158/0008-5472.CAN-07-0320]
93. Dakin LA, Block MH, Chen H, Code E, Dowling JE, Feng X, Ferguson AD, Green I, Hird AW, Howard T, Keeton EK, Lamb ML, Lyne PD, Pollard H, Read J, Wu AJ, Zhang T, Zheng X. Discovery of novel benzylidene-1,3-thiazolidine- 2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinases. Bioorg Med Chem Lett 2012; 22: 4599-4604 [PMID: 22727640 DOI: 10.1016/j.bmcl.2012.05.098]
94. Xia Z, Knaak C, Ma J, Beharry ZM, McInnes C, Wang W, Kraft AS, Smith CD. Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases. J Med Chem 2009; 52: 74-86 [PMID: 19072652 DOI: 10.1021/jm800937p]
95. Lin YW, Beharry ZM, Hill EG, Song JH, Wang W, Xia Z, Zhang Z, Aplan PD, Aster JC, Smith CD, Kraft AS. A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma. Blood 2010; 115: 824-833 [PMID: 19965690 DOI: 10.1182/blood-2009-07-233445]
96. Nishiguchi GA, Atallah G, Bellamacina C, Burger MT, Ding Y, Feucht PH, Garcia PD, Han W, Klivansky L, Lindvall M. Discovery of novel 3,5-disubstituted indole derivatives as potent inhibitors of Pim-1, Pim-2, and Pim-3 protein kinases. Bioorg Med Chem Lett 2011; 21: 6366-6369 [PMID: 21945284 DOI: 10.1016/j.bmcl.2011.08.105]
97. Gavara L, Saugues E, Alves G, Debiton E, Anizon F, Moreau P. Synthesis and biological activities of pyrazolo[3,4-g]quinoxaline derivatives. Eur J Med Chem 2010; 45: 5520-5526 [PMID: 20864224 DOI: 10.1016/j.ejmech.2010.08.067]
98. Suchaud V, Gavara L, Saugues E, Nauton L, Théry V, Anizon F, Moreau P. Identification of 1,6-dihydropyrazolo[4,3-c]carbazoles and 3,6-dihydropyrazolo[3,4-c]carbazoles as new Pim kinase inhibitors. Bioorg Med Chem 2013; 21: 4102-4111 [PMID: 23735828 DOI: 10.1016/j.bmc.2013.05.011]
99. Akué-Gédu R, Letribot B, Saugues E, Debiton E, Anizon F, Moreau P. Kinase inhibitory potencies and in vitro antiproliferative activities of N-10 substituted pyrrolo[2,3-a]carbazole derivatives. Bioorg Med Chem Lett 2012; 22: 3807-3809 [PMID: 22543026 DOI: 10.1016/j.bmcl.2012.03.098]
100. Gavara L, Suchaud V, Nauton L, Théry V, Anizon F, Moreau P. Identification of pyrrolo[2,3-g]indazoles as new Pim kinase inhibitors. Bioorg Med Chem Lett 2013; 23: 2298-2301 [PMID: 23499503 DOI: 10.1016/j.bmcl.2013.02.074]
101. Letribot B, Akué-Gédu R, Santio NM, El-Ghozzi M, Avignant D, Cisnetti F, Koskinen PJ, Gautier A, Anizon F, Moreau P. Use of copper(I) catalyzed azide alkyne cycloaddition (CuAAC) for the preparation of conjugated pyrrolo[2,3-a]carbazole Pim kinase inhibitors. Eur J Med Chem 2012; 50: 304-310 [PMID: 22386260 DOI: 10.1016/j.ejmech.2012.02.009]
102. Li YY, Wang YY, Taniguchi T, Kawakami T, Baba T, Ishibashi H, Mukaida N. Identification of stemonamide synthetic intermediates as a novel potent anticancer drug with an apoptosis-inducing ability. Int J Cancer 2010; 127: 474-484 [PMID: 19921695 DOI: 10.1002/ijc.25048]
103. Wang Z, Li XM, Shang K, Zhang P, Wang CF, Xin YH, Zhou L, Li YY. T-18, a stemonamide synthetic intermediate inhibits Pim kinase activity and induces cell apoptosis, acting as a potent anticancer drug. Oncol Rep 2013; 29: 1245-1251 [PMID: 23314349 DOI: 10.3892/or.2013.2233]
104. Akué-Gédu R, Rossignol E, Azzaro S, Knapp S, Filippakopoulos P, Bullock AN, Bain J, Cohen P, Prudhomme M, Anizon F, Moreau P. Synthesis, kinase inhibitory potencies, and in vitro antiproliferative evaluation of new Pim kinase inhibitors. J Med Chem 2009; 52: 6369-6381 [PMID: 19788246 DOI: 10.1021/jm901018f]
105. Rhodes N, Heerding DA, Duckett DR, Eberwein DJ, Knick VB, Lansing TJ, McConnell RT, Gilmer TM, Zhang SY, Robell K, Kahana JA, Geske RS, Kleymenova EV, Choudhry AE, Lai Z, Leber JD, Minthorn EA, Strum SL, Wood ER, Huang PS, Copeland RA, Kumar R. Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res 2008; 68: 2366-2374 [PMID: 18381444 DOI: 10.1158/0008-5472.CAN-07-5783]
106. Chen WS, Xu PZ, Gottlob K, Chen ML, Sokol K, Shiyanova T, Roninson I, Weng W, Suzuki R, Tobe K, Kadowaki T, Hay N. Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. Genes Dev 2001; 15: 2203-2208 [PMID: 11544177 DOI: 10.1101/gad.913901]
107. Easton RM, Cho H, Roovers K, Shineman DW, Mizrahi M, Forman MS, Lee VM, Szabolcs M, de Jong R, Oltersdorf T, Ludwig T, Efstratiadis A, Birnbaum MJ. Role for Akt3/protein kinase Bgamma in attainment of normal brain size. Mol Cell Biol 2005; 25: 1869-1878 [PMID: 15713641 DOI: 10.1128/MCB.25.5.1869-1878.2005]
108. Woulfe D, Jiang H, Morgans A, Monks R, Birnbaum M, Brass LF. Defects in secretion, aggregation, and thrombus formation in platelets from mice lacking Akt2. J Clin Invest 2004; 113: 441-450 [PMID: 14755341 DOI: 10.1172/JCI20267]